January 21, 2020
Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly diagnosed glioblastoma. The medical services basket includes the entire range of services, medications… Read More
learn more
January 13, 2020
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on Monday, Jan. 13, 2020 Fourth quarter and full year 2019 financial results to… Read More
learn more
January 9, 2020
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
SHANGHAI & ST. HELIER, Jersey–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2… Read More
learn more
